MX2018002640A - Seleccion de pacientes para la terapia de combinacion. - Google Patents

Seleccion de pacientes para la terapia de combinacion.

Info

Publication number
MX2018002640A
MX2018002640A MX2018002640A MX2018002640A MX2018002640A MX 2018002640 A MX2018002640 A MX 2018002640A MX 2018002640 A MX2018002640 A MX 2018002640A MX 2018002640 A MX2018002640 A MX 2018002640A MX 2018002640 A MX2018002640 A MX 2018002640A
Authority
MX
Mexico
Prior art keywords
combination therapy
patients
selection
entinostat
methods
Prior art date
Application number
MX2018002640A
Other languages
English (en)
Inventor
Ordentlich Peter
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2018002640A publication Critical patent/MX2018002640A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Se describen en la presente métodos para seleccionar pacientes con cáncer para el tratamiento con una terapia de combinación que comprende entinostat y un segundo agente terapéutico; en particular, se proporcionan métodos para el examen de células supresoras derivadas de mieloides, tipo células no cancerosas, por ejemplo, las que son CD14-positivas y HLA-DR-(lo/negativas), como un indicador terapéutico en el entorno de terapias de combinación entinostat.
MX2018002640A 2015-09-02 2016-09-02 Seleccion de pacientes para la terapia de combinacion. MX2018002640A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213288P 2015-09-02 2015-09-02
US201562219612P 2015-09-16 2015-09-16
PCT/US2016/050274 WO2017041043A1 (en) 2015-09-02 2016-09-02 Selection of patients for combination therapy

Publications (1)

Publication Number Publication Date
MX2018002640A true MX2018002640A (es) 2018-06-20

Family

ID=58188549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002640A MX2018002640A (es) 2015-09-02 2016-09-02 Seleccion de pacientes para la terapia de combinacion.

Country Status (14)

Country Link
US (2) US11397184B2 (es)
EP (1) EP3345002A4 (es)
JP (2) JP2018527570A (es)
KR (2) KR102631377B1 (es)
CN (2) CN108139403B (es)
AU (2) AU2016318136B2 (es)
BR (1) BR112018003238A2 (es)
CA (1) CA2994731C (es)
HK (1) HK1258128A1 (es)
IL (1) IL257355B (es)
MX (1) MX2018002640A (es)
RU (1) RU2018111407A (es)
WO (1) WO2017041043A1 (es)
ZA (1) ZA201800931B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3270966B1 (en) * 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc. Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine.
WO2017132536A1 (en) 2016-01-28 2017-08-03 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
MX2020011761A (es) * 2018-05-07 2021-04-28 Syndax Pharmaceuticals Inc Selección de pacientes para terapia de combinación.
CN109251891B (zh) * 2018-09-21 2021-10-22 苏州大学附属第一医院 一种cd40联合pd-l1及细胞因子扩增pbmc的方法
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUD20080058A1 (it) * 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
CN103608028A (zh) * 2011-04-28 2014-02-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
CN114053284A (zh) * 2011-09-02 2022-02-18 辛达克斯制药股份有限公司 治疗乳腺癌的方法
WO2014011713A2 (en) 2012-07-10 2014-01-16 Dana-Farber Cancer Institue, Inc. Anti-proliferative compounds and uses thereof
US20140205669A1 (en) 2012-11-29 2014-07-24 The Penn State Research Foundation dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR
CA2955177A1 (en) 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
EP3270966B1 (en) * 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc. Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine.

Also Published As

Publication number Publication date
CA2994731C (en) 2023-09-26
RU2018111407A3 (es) 2020-02-10
WO2017041043A1 (en) 2017-03-09
US20180252721A1 (en) 2018-09-06
IL257355B (en) 2021-10-31
AU2022246409A1 (en) 2022-11-03
CN108139403B (zh) 2023-05-09
CN108139403A (zh) 2018-06-08
KR20180048703A (ko) 2018-05-10
IL257355A (en) 2018-04-30
EP3345002A1 (en) 2018-07-11
HK1258128A1 (zh) 2019-11-08
KR20240017973A (ko) 2024-02-08
EP3345002A4 (en) 2019-05-08
US20230061048A1 (en) 2023-03-02
AU2016318136B2 (en) 2022-10-20
AU2016318136A1 (en) 2018-02-22
US11397184B2 (en) 2022-07-26
ZA201800931B (en) 2023-12-20
JP7206352B2 (ja) 2023-01-17
JP2022009460A (ja) 2022-01-14
BR112018003238A2 (pt) 2018-09-25
KR102631377B1 (ko) 2024-01-29
CN116893262A (zh) 2023-10-17
RU2018111407A (ru) 2019-10-03
CA2994731A1 (en) 2017-03-09
JP2018527570A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
ZA201800931B (en) Selection of patients for combination therapy
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
PH12017502153A1 (en) Diagnostic methods for t cell therapy
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
IL283325A (en) Treatment methods using adoptive cellular therapy
MY181994A (en) Immuno-modulatory progenitor (imp) cell
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
PH12018502147A1 (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
HK1245096A1 (zh) 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
EP3314250A4 (en) Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
SG11202101071WA (en) Proton therapy gantry
PH12021550035A1 (en) Combination therapy
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
EP3531830A4 (en) METHODS AND COMPOSITIONS FOR IDENTIFICATION AND TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER
MX2017016346A (es) Metodos de tratamiento con taselisib.
MX2017014540A (es) Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus.
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.